Abstract | BACKGROUND: The Early Treatment for Retinopathy of Prematurity trial demonstrated that peripheral retinal ablation of eyes with high-risk prethreshold retinopathy of prematurity (early treatment) is associated with improved visual outcomes at 9 months' corrected gestational age compared with treatment at threshold disease (conventional management). However, early treatment increased the frequency of laser therapy, anesthesia with intubation, treatment-related systemic complications, and the need for repeat treatments. OBJECTIVE: To determine the cost-effectiveness of an early treatment strategy for retinopathy of prematurity compared with conventional management. DESIGN/METHODS: We developed a stochastic decision analytic model to assess the incremental cost of early treatment per eye with severe visual impairment prevented. We derived resource-use and efficacy estimates from the Early Treatment for Retinopathy of Prematurity trial's published outcome data. We used a third-party payer perspective. Our primary analysis focused on outcomes from birth through 9 months' corrected gestational age. A secondary analysis used a lifetime horizon. Parameter uncertainty was quantified by using probabilistic and deterministic sensitivity analyses. RESULTS: The incremental cost-effectiveness of early treatment was $14,200 per eye with severe visual impairment prevented. There was a 90% probability that the cost-effectiveness of early treatment would be less than $40,000 per eye with severe visual impairment prevented and a 0.5% probability that early treatment would be cost-saving (less costly and more effective). Limiting early treatment to more severely affected eyes (eyes with "type 1 retinopathy of prematurity" as defined by the Early Treatment for Retinopathy of Prematurity trial) had a cost-effectiveness of $6,200 per eye with severe visual impairment prevented. Analyses that considered long-term costs and outcomes found that early treatment was cost-saving. CONCLUSIONS: Early treatment of retinopathy of prematurity is both efficacious and economically desirable. Because of the high lifetime costs of severe visual impairment, the early treatment strategy provides long-term cost savings.
|
Authors | Karen L Kamholz, Cynthia H Cole, James E Gray, John A F Zupancic |
Journal | Pediatrics
(Pediatrics)
Vol. 123
Issue 1
Pg. 262-9
(Jan 2009)
ISSN: 1098-4275 [Electronic] United States |
PMID | 19117891
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Cost-Benefit Analysis
(methods)
- Decision Trees
- Humans
- Infant, Newborn
- Infant, Premature
- Models, Economic
- Multicenter Studies as Topic
(economics)
- Randomized Controlled Trials as Topic
(economics)
- Retinopathy of Prematurity
(economics, therapy)
- Time Factors
- Treatment Outcome
|